Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25853272 | 0.88 | SLC6A2 (0.33) | HTR2AHRH1AOC3TDP1 | |
| SCHEMBL25833265 | 0.87 | TRPM8 (0.39) | HTR2AHRH1AOC3GBA1TRPM8 | |
| SCHEMBL25833306 | 0.87 | AOC3 (0.31) | HTR2AHRH1AOC3 | |
| SCHEMBL4662642 | 0.80 | AOC3 (0.51) | HTR2AHRH1AOC3TDP1SLC22A1 | |
| SCHEMBL19993093 | 0.78 | AOC3 (0.48) | HTR2AHRH1AOC3TDP1 | |
| SCHEMBL21787711 | 0.78 | AOC3 (0.48) | HTR2AHRH1AOC3TDP1 | |
| SCHEMBL23360961 | 0.77 | GBA1 (0.46) | HTR2AHRH1AOC3TDP1GBA1 | |
| SCHEMBL25257597 | 0.77 | HTR2A (0.34) | HTR2AHRH1AOC3TDP1GBA1 | |
| SCHEMBL25257589 | 0.77 | AOC3 (0.47) | HTR2AHRH1AOC3TDP1GBA1 | |
| SCHEMBL25852688 | 0.76 | HTR2A (0.37) | HTR2AHRH1AOC3TDP1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | HTR2A 1968/4885HRH1 2554/4885AOC3 3111/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | HTR2A 1968/4885HRH1 2554/4885AOC3 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.